BioStock: BioInvent presents several projects at AACR’s annual meeting

Between April 8 to 13, the annual meeting of the American Association for Cancer Research takes place. One of the participants is Swedish pharmaceutical company BioInvent, which will present several new data regarding the drug candidates BI-1607, BI-1808 and BT-001. The latter two are currently undergoing phase I/II studies evaluating safety and early indications of efficacy. The plan is to enroll the first patient in the clinical study with BI-1607 during the second quarter of this year.

Read the full article about BioInvent at biostock.se:

https://www.biostock.se/en/2022/03/bioinvent-presents-several-projects-at-aacrs-annual-meeting/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/